Mazda and the ACCC race to win appeal in the Full Federal Court
10 May 2022
Both the ACCC and Mazda have appealed a Federal Court decision which found that Mazda had mislead consumers but not acted unconscionably...
Read on
appeal
Appealing domestic arbitral awards in Australia: not opting out is not opting in
3 December 2020
This article provides a summary of Jacobs Group v Commonwealth Australia and its implications on the appeal of domestic arbitral awards in Australia
Read on
The Appeal of the Law: Singapore’s decision to hold off introduction option to appeal on point of law and other changes
1 November 2020
The right to appeal an arbitral award on questions of law is not uncommon. Singapore has yet to adopt this right into its IAA legislation.
Read on
A very modest win: Generic Health gets 2% cut to Bayer’s $25 million damages
8 November 2018
Last year, Bayer was awarded more than $25 million (plus interest and indemnity costs) against Generic Health in the first Federal Court award of damages for pharmaceutical patent infringement.
Read on
Smells fishy: Trident Seafoods Corporation v Trident Foods Pty Limited
19 October 2018
This recent Federal Court decision concerns two appeals by Trident Seafoods Corporation (Trident Seafoods) from decisions made by delegates of the Registrar of Trade Marks.
Read on
United States Court of Appeals upholds PTAB decision on CRISPR Patent Interference
24 September 2018
Regents of the University of California & Ors v Broad Institute, Inc.
Read on
What do you know about a ‘smoking gun’?
5 June 2018
The Full Court of the Federal Court has handed down its decision in the ACCC's appeal of the Pfizer case. The case considers 'smoking gun' documents.
Read on
Second throw of the dice unsuccessful: Full Federal Court confirms Hepatitis C drug patent is invalid
21 December 2017
The recent decision of the Full Court in Idenix Pharmaceuticals v Gilead Sciences [2017] FCAFC 196 illustrates the power of the grounds of lack of utility and lack of sufficiency under section 40 of the Patents Act when challenging the validity of a patent.
Read on
Full Court warns against dangerous affliction of parameteritis (and confirms invalidity of aripiprazole patent)
26 August 2016
On Wednesday the Full Court of the Federal Court of Australia handed down a decision in which it upheld Justice Yates’ findings that Otsuka’s patent relating to aripiprazole, a drug used in the treatment of schizophrenia, is invalid for want of novelty and inventive step.
Read on